Kisspeptin 10mg

Kisspeptin is a signal made in the hypothalamus that tells GnRH neurons to fire, which in turn prompts the pituitary to release LH and FSH, the hormones that drive the testes and ovaries. Kisspeptin-10 is a short fragment of the natural peptide that keeps that signaling activity. Clinical researchers have used it to study the reproductive axis because it acts so high up the chain.

Yes. A 2011 study found kisspeptin-10 raised LH and FSH in healthy men at low doses, but did not raise them in women during the early follicular phase of the menstrual cycle, only around ovulation. Later research confirmed that the response in women changes across the cycle. That is why BHRC times labs carefully and why a plan that suits a man may not suit a woman.

Small studies at Imperial College London found kisspeptin changed brain activity in response to sexual images, and a 2023 randomized crossover trial that enrolled 37 men with low sexual desire reported increased brain responses and some secondary improvements in arousal measures. These are early, short-term, laboratory studies. They are interesting, but they do not establish kisspeptin as a libido treatment, and BHRC does not present it as one.

Researchers have studied kisspeptin as a trigger for final egg maturation in IVF, largely to reduce the risk of ovarian hyperstimulation. That work happens in specialist fertility units under research protocols. BHRC does not provide IVF or ovulation-trigger care; if fertility is your goal, the clinic will coordinate with or refer you to a reproductive endocrinologist.

Dosing is individualized after hormone testing, so it is not listed here. For background reading on how protocols have been described, see our Kisspeptin-10 Dosage Guide. Please use it to prepare questions for your provider, not to self-dose.

That is not well established. A 2026 study in healthy men found daily eight-hour subcutaneous kisspeptin-10 infusions sustained LH and testosterone rises over 12 days, while continuous exposure for several days blunted the gonadotropin response. Data beyond a few weeks are thin, which is one reason BHRC uses short, lab-reviewed trials. It also means the clinic will not promise that a response seen in the first month will persist, and builds a recheck into every plan.

Research studies have generally reported few side effects over short periods, but those were small, controlled studies, often using kisspeptin made to clinical-trial standards. Hormone-related effects such as mood change or breast tenderness, injection-site reactions and headache are the things the clinic watches for.

Cost depends on the length of the trial, the number of vials, and the repeat hormone panels, which are a meaningful part of a responsible plan. BHRC does not publish prices on this page; you receive a full quote after the consultation. It is not covered by insurance. If the baseline panel shows a medical problem that needs standard care, the cost of that care is separate and may be covered by your plan.

It means FDA has identified significant safety concerns with compounding this substance and would consider taking action against compounders who use it. For you, it means less certainty about product quality and long-term safety. BHRC explains this before prescribing, so you can decide with the full picture.

Testosterone replaces the end hormone and tends to switch off your own production. Gonadorelin acts one step lower, at the pituitary. Kisspeptin acts above both, at the hypothalamic level. Which, if any, is appropriate depends on where in the axis the problem sits, which is what the baseline labs are for. In practice, many people who ask about kisspeptin end up on a different plan once their labs are back, and that is a good outcome, not a failure of the consult.